4SC AG Logo

4SC AG

Biopharmaceutical company with no products under development or operational business.

VSC | F

Overview

Corporate Details

ISIN(s):
DE000A3E5C40
LEI:
391200QOKN7LGVP0RQ86
Country:
Germany
Address:
Fraunhoferstr. 22, 82152 Planegg

Description

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2017-07-11 16:31
DGAP-DD: 4SC AG english
English HTML 7.1 KB
2017-07-11 16:24
DGAP-DD: 4SC AG english
English HTML 7.1 KB
2017-07-06 18:51
4SC AG secures EUR 41 million from successful capital increase
English HTML 19.1 KB
2017-06-28 12:21
4SC AG announces subscription price for new shares from current capital increase
English HTML 19.7 KB
2017-06-12 18:03
4SC AG resolves to issue new shares to continue to advance its drug development…
English HTML 21.8 KB
2017-05-30 07:30
4SC AG: Resminostat enhances immune cell cancer cell interaction
English HTML 13.0 KB
2017-05-16 11:35
4SC AG announces updated and progressive development program
English HTML 29.4 KB
2017-05-16 11:29
4SC AG announces updated and progressive development program
English HTML 21.8 KB
2017-05-03 07:30
4SC AG: Progress update on pivotal RESMAIN study of resminostat in CTCL at 13th…
English HTML 16.4 KB
2017-04-27 07:30
4SC provides Q1 2017 update
English HTML 11.9 KB
2017-04-27 00:00
Q1 statement / Q1 financial report 2017
English PDF 941.7 KB
2017-04-11 07:30
4SC AG: New mechanistic insights into 4SC-202's epigenetic mode of action
English HTML 17.0 KB
2017-04-04 15:39 English HTML 17.7 KB
2017-04-04 15:23 English HTML 17.6 KB
2017-03-31 00:00
Annual financial report 2016
English PDF 4.3 MB

Automate Your Workflow. Get a real-time feed of all 4SC AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 4SC AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 4SC AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900
ABEONA THERAPEUTICS INC. Logo
A clinical-stage biopharma developing cell and gene therapies for rare diseases.
United States of America
ABEO

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.